Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Advanced Micro Devices (AMD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Advanced Micro Devices — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.76 (market cap $4.49B), while Advanced Micro Devices trades at $511.51 (market cap $841.57B). The key difference: Advanced Micro Devices is far larger — about 187.4× ACADIA Pharmaceuticals Inc.'s market cap, and Advanced Micro Devices is trading nearer its 52-week high, ACADIA Pharmaceuticals Inc. nearer its low. Which is the better fit depends on your goals.
| ACAD | AMD | |
|---|---|---|
Market Cap | $4.49B | $841.57B |
Sector | Health | Technology |
52-Week High | $28.06 | $580.91 |
52-Week Low | $20.06 | $137.82 |
Enterprise Value | $3.69B | $833.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
AMD trades at $552.05, up 6.61% today and near its 52-week high, with strong technical momentum and bullish moving averages. The company reported robust Q1 2026 earnings of $1.37 EPS, beating expectations, and shows accelerating revenue growth to $34.64 billion in 2025 with net income surging to $4.34 billion. Analyst sentiment remains overwhelmingly positive with 71% buy ratings.
AMD's AI-driven growth trajectory presents significant upside potential, though premium valuations (P/E 184) and intense semiconductor competition pose risks. The stock's technical strength and fundamental momentum support continued bullish sentiment, but investors should monitor execution against high expectations and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Advanced Micro Devices
Advanced Micro Devices, Inc. (AMD) produces semiconductor products and devices. The Company offers products such as microprocessors, embedded microprocessors, chipsets, graphics, video and multimedia products and supplies it to third-party foundries, as well as provides assembling, testing, and packaging services. AMD serves customers worldwide.
Read more on AMD →
